Canbiola is Registered and Active in the GSA's System for Award Management (SAM) and Department of Defense (DOD)
March 14 2019 - 9:00AM
InvestorsHub NewsWire
HICKSVILLE, NY, March 14, 2019 -- InvestorsHub
NewsWire -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the
“Company”), a developer, manufacturer and seller of a
variety of Cannabidiol (Hemp) based products such as oils, creams,
moisturizers, chews, isolate, gel caps, and concentrate, announced
today that it is now registered and active in the U.S.
government GSA’s System for Award Management (SAM) and Department
of Defense (DOD).
System for Award Management. SAM is streamlining processes,
improving data quality by eliminating the need to enter the same
data multiple times, and consolidating hosting to save taxpayer
money. The System for Award Management (SAM) is an official website
of the U.S. government. There is no cost to use SAM. GSA’s Office
of Government-wide Policy is consolidating federal procurement and
award systems into 1 new system—the System
for Award Management (SAM). SAM is streamlining processes,
improving data quality by eliminating the need to enter the same
data multiple times, and consolidating hosting to save taxpayer
money.
The registration number for Canbiola, Inc. is 789110553
/ 5C7D3 and is now active in the U.S. federal government's System
for Award Management (SAM/DOD).
For additional information, please visit:
https://www.sam.gov/SAM/
https://www.acq.osd.mil/dpap/pdi/eb/system_for_award_management.html
Canbiola Chief Executive
Officer Marco Alfonsi, commented, "Attaining SAM and DOD
registration is quite an accomplishment and something our team at
Canbiola had been working on for some time. We are proud to now be
active in the system, which enables our products to be more widely
available to those who seek CBD solutions. We look forward to being
an active participant in the U.S. government
program. Canbiola Chief
Executive Officer Marco Alfonsi, commented, “Attaining SAM and DOD
registration is quite an accomplishment and something our team at
Canbiola had been working on for some time. We are proud to now be
active in the system, which enables our products to be more widely
available to those who seek CBD solutions. We look forward to being
an active participant in the U.S. government program.”
About Canbiola, Inc.
Canbiola, Inc.
(OTCQB: CANB) is a developer,
manufacturer and seller of a variety of Cannabidiol (Hemp) based
products such as oils, creams, moisturizers, chews,, isolate, gel
caps, and concentrates. Canbiola has developed its own line of
proprietary products as well as seeking synergistic value through
acquisitions in the CBD and the medical cannabis industry. Cannabis
is currently federally illegal and has legalized for medical
purposes in some form in a limited number of states, but pure CBD
products are legal in all 50 states. Hemp CBD is the
non-psychoactive component (No THC) used for treatment of pain,
inflammation, and wellness programs. For more
information about Canbiola, Inc., please visit: https://canbiola.com.
Additionally, Canbiola’s wholly owned subsidiary Pure
Health Products, based in Lacey, WA, is its prime development
laboratory and production facility. Canbiola’s Duramed
division has recently rolled out a durable medical device via its
Doctor network to treat patients with injuries via application of
an in-home ultrasound sustained acoustic device for pain and
inflammation reduction.
Forward-Looking Statements
Forward-looking statements and risks and uncertainties
discussed in this letter contain forward-looking statements. The
words "anticipate," "believe," "estimate," "may," "intend,"
"expect," and similar expressions identify such forward-looking
statements. Expected, actual results, performance, or achievements
could differ materially from those contemplated, expressed, or
implied by the forward-looking statements contained herein.
Forward-looking statements are subject to a number of risks and
uncertainties, including but not limited to, risks and
uncertainties associated with, among other things, the impact of
economic, competitive, and other factors affecting our operations,
markets, products, and performance. The matters discussed herein
should not be construed in any way, shape or manner of our future
financial condition or stock price.
Follow Canbiola on:
Twitter
@CanbiolaHealth
Instagram @canbiola.inc or @canbiola_cbd or
@canbiola_medical_cbd
Follow us
on Twitter and Facebook
Investors and Media:
IR@canbiola.com
(516) 595-9544
Hayden IR
hart@haydenir.com
(917) 658-7878
CAN B (QB) (USOTC:CANB)
Historical Stock Chart
From Aug 2024 to Sep 2024
CAN B (QB) (USOTC:CANB)
Historical Stock Chart
From Sep 2023 to Sep 2024